Physician profile
John Campobasso
NPI 1730150566
$5,190.89
in general payments reported to CMS, 2019-2025
36 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $556 · 2021: $824 · 2022: $87.56 · 2023: $577 · 2024: $1,230 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.81 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,150.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $770.13 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbott Laboratories | $633.94 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $407.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $371.34 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $269.07 | 2020-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $241.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.94 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $119.05 | 2019-2021 | |
| Glaxosmithkline, LLC. | $91.53 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $89.52 | 2019-2025 | Eliquis |
| Astellas Pharma US INC | $88.28 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $75.96 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $74.06 | 2023-2024 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $53.16 | 2020-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Campobasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.